US · NVCT
Nuvectis Pharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Fort Lee, NJ 07024
- Website
- nuvectis.com
Price · as of 2025-12-31
$8.54
Market cap 234.72M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $8.27 | ||||
| 2022 | $10.77 | ||||
| 2023 | $10.26 | ||||
| 2024 | $6.93 | ||||
| 2025 | $9.04 |
AI valuation
Our deep-learning model estimates Nuvectis Pharma, Inc.'s (NVCT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $8.54
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NVCT | Nuvectis Pharma, Inc. | $8.54 | 234.72M | — | — | — | — | -7.46 | 10.71 | — | -6.00 | -39.42 | 10.71 | 0.00% | — | — | -188.03% | 250.21% | -105.10% | 0.00 | — | 2.38 | 2.38 | 1.15 | 1892.00% | — | 3072.00% | -8.12% | -1.20 | 145.27% | 0.00% | 0.00% | 6.64% | -6.00 | -10.34 | — | 2.32 |
| CGEN | Compugen Ltd. | $1.81 | 169.3M | +2,407% | -50% | — | -30% | -10.44 | 2.71 | 5.33 | -3.35 | — | 2.71 | 71.54% | -53.44% | -51.07% | -23.63% | 101.98% | -12.04% | 0.05 | -437.97 | 5.26 | 5.14 | 1.06 | -2381.00% | -1672.00% | -23724.00% | 33.30% | 2.46 | -338.90% | 0.00% | 0.00% | 1.87% | -3.24 | 0.98 | 1.73 | -3.76 |
| CRDF | Cardiff Oncology, Inc. | $1.94 | 130.68M | +1,196% | -60% | — | +59% | -2.83 | 2.86 | 218.67 | -1.61 | — | 2.86 | -52.45% | -8256.32% | -7736.26% | -71.45% | 505.84% | -57.65% | 0.02 | — | 3.67 | 3.57 | 0.37 | -2737.00% | -1318.00% | 51.00% | -29.28% | -2.31 | 392.26% | 0.00% | 0.00% | 0.00% | -1.47 | -1.90 | 121.75 | -6.77 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| RANI | Rani Therapeutics Holding… | $1.37 | 100M | — | -55% | — | — | -0.79 | 22.30 | 43.21 | -0.92 | — | 22.30 | 100.00% | -5186.19% | -2920.04% | -761.66% | 7052.12% | -119.69% | 14.91 | -10.59 | 1.50 | 1.41 | -0.51 | -2105.00% | — | -3183.00% | -80.51% | -1.78 | 4730.69% | 0.00% | 0.00% | 0.00% | -0.87 | -1.30 | 45.23 | -7.58 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| TNXP | Tonix Pharmaceuticals Hol… | $13.97 | 178.65M | -2% | -63% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
- CEO
- Ron Bentsur
- Employees
- 13
- Beta
- -0.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $8.54) − 1 = — (DCF, example).